Revvity and Sanofi Collaborate to Advance Early Screening for Type 1 Diabetes with Novel Quadruple Antibody Diagnostic Test

The diagnosis of diabetes is moving from "management after diagnosis" to "identification before onset."

Recently, a globally renowned in vitro diagnostics companyRevvityAnnouncement with pharmaceutical giantSanofiReach cooperation, jointly develop a product forEarly Detection of Type 1 Diabetes (T1D)In vitro diagnostic tests.

The goal of this collaboration is to enable doctors to identify high-risk populations before diseases actually manifest, creating possibilities for early intervention.

Currently, Revvity has a triple assay for research use only (RUO), which can detect multiple autoantibodies associated with type 1 diabetes through dried blood spots or venous blood samples.

This collaboration with Sanofi will expand the platform toQuadruple Antibody Test, and promote its transformation into a clinically available registered product. This means that testing will move from research laboratories to hospitals, becoming an early screening tool in the hands of clinicians.

The project plans to utilize Revvity's GSP instrument platform to complete clinical validation and registration work on a global scale. Sanofi stated that it hopes, through this collaboration, to integrate the concept of "early identification and intervention in the autoimmune destruction process" into routine future diabetes management practices.

Almost simultaneously with this progress, the U.S. startupKihealthAnnounced Completion$5 Million Seed Round FinancingThis company is developing a technology to assess the health status of pancreatic β cells through blood tests, aiming to identify individuals who "have not yet shown abnormal blood sugar levels but already have cellular damage." In other words, they want to capture the "pre-signals" of the disease—detecting the early decline in islet function before blood sugar levels rise.

Kihealth's goal is to apply such testing in routine physical exams or chronic disease management, thereby identifying potential future diabetes patients in advance. This creates an interesting parallel with Revvity–Sanofi’s direction: the former focuses on immune signals, while the latter centers on cellular function, together forming the dual pathways for early diabetes detection.

In the past diabetes diagnosis system, doctors usually relied on indicators such as blood glucose and HbA1c to assess the condition, but these changes often appear at a relatively advanced stage of the disease. Nowadays, technological advancements give us the opportunity to "diagnose years in advance," reading the warning signs of the disease before symptoms manifest in the body.

From research to clinical practice, from metabolic indicators to immune markers, these changes signify that diabetes testing is undergoing a "revolution in the time dimension."It is no longer just about discovering diseases, but rather going toPredicting Diseases, Preventing Diseases。

For in vitro diagnostic companies in China, this trend also represents a new opportunity: in the field of early screening and risk prediction, whoever can first overcome the technical and compliance barriers may gain an advantage in the chronic disease management market of the next era.

Add the editor-in-chief to the IVD group

Statement:This article only represents the author's viewpoint and does not reflect the platform's position.If the reprint involves copyright and other issues, please contact us as soon as possible. We will correct or delete it in the first instance. Thank you!